<SEC-DOCUMENT>0001021561-14-000058.txt : 20140516
<SEC-HEADER>0001021561-14-000058.hdr.sgml : 20140516
<ACCEPTANCE-DATETIME>20140516151200
ACCESSION NUMBER:		0001021561-14-000058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140516
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140516
DATE AS OF CHANGE:		20140516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NU SKIN ENTERPRISES INC
		CENTRAL INDEX KEY:			0001021561
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				870565309
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12421
		FILM NUMBER:		14851206

	BUSINESS ADDRESS:	
		STREET 1:		75 WEST CENTER ST
		STREET 2:		ATTN: D. MATTHEW DORNY
		CITY:			PROVO
		STATE:			UT
		ZIP:			84601
		BUSINESS PHONE:		801-345-6100

	MAIL ADDRESS:	
		STREET 1:		75 WEST CENTER ST
		STREET 2:		ATTN: D. MATTHEW DORNY
		CITY:			PROVO
		STATE:			UT
		ZIP:			84601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NU SKIN ASIA PACIFIC INC
		DATE OF NAME CHANGE:	19960919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>may162014.htm
<DESCRIPTION>FORM 8-K MAY 16, 2014
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: j
    Document created using Disclosure Solutions PROFILE 2.5.3.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#173;UNITED STATES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Washington, D.C. 20549</div>

<div><br>
</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FORM 8-K</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CURRENT REPORT</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

<div><br>
</div>

<table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">May 16, 2014</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: top" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">Date of Report (Date of earliest event reported)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="3">
<div style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">NU SKIN ENTERPRISES, INC.</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: top" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(Exact name of registrant as specified in its charter)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Delaware</div>
</td>
<td style="WIDTH: 12.92%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 26.55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">001-12421</div>
</td>
<td style="WIDTH: 13.63%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">87-0565309</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(State or other jurisdiction of incorporation)</div>
</td>
<td style="WIDTH: 12.92%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 26.55%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(Commission File Number)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 13.63%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(IRS Employer Identification Number)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">75 West Center Street</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Provo, UT 84601</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: top" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(Address of principal executive offices and zip code)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(801) 345-1000</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: top" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(Registrant's telephone number, including area code)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">N/A</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 23.36%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 53.1%; VERTICAL-ALIGN: top" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: center">(Former name or former address, if changed since last report)</div>

<div>&#160;</div>
</td>
<td style="WIDTH: 23.54%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif">&#9633;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 6pt">&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif">&#9633;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 6pt">&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left">
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#9633;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left">
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 14pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: 18pt; VERTICAL-ALIGN: top; align: right">&#9633;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">An electronic copy of the Letter to Shareholders, excerpted from the Nu Skin Enterprises, Inc.&#160;2013 Annual Report to Shareholders, as attached hereto as Exhibit 99.1 is not filed, but is furnished pursuant to Regulation FD.&#160; The 2013 Annual Report to Shareholders will be first sent or given to our shareholders on or about May 16, 2014.&#160; A complete copy of the 2013 Annual Report to Shareholders can be obtained on our website, <font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif">www.nuskinenterprises.com</font> or by contacting our Investor Relations Department, telephone: 801-345-6100, e-mail: <font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif">spond@nuskin.com</font>, address: 75 West Center Street, Provo, UT&#160; 84601.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 9.01 <font style="FONT-SIZE: 1px; LETTER-SPACING: 9pt">&#160;&#160;</font>Financial Statements and Exhibits.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">99.1 &#160;&#160;&#160;&#160;&#160; Letter to Shareholders, excerpted from the Nu Skin Enterprises, Inc. 2013 Annual Report to Shareholders.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div><br>
</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SIGNATURE</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 216pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">NU SKIN ENTERPRISES, INC.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif"><br>
</font> (Registrant)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 216pt"><u>/s/ Ritch N. Wood</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 216pt">Ritch N. Wood<font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif"><br>
</font> Chief Financial Officer</div>

<div><br>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Date:&#160; May 16, 2014</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT INDEX</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif"><u>Exhibit No.</u></font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.02pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold"><u>Exhibit Description</u></font></div>

<div style="TEXT-ALIGN: left">
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: 108pt; VERTICAL-ALIGN: top; align: right">99.1</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">Letter to Shareholders, excerpted from the Nu Skin Enterprises, Inc.&#160; 2013 Annual Report to Shareholders.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left; MARGIN-LEFT: 216pt; TEXT-INDENT: -216pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: j
    Document created using Disclosure Solutions PROFILE 2.5.3.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 12pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Exhibit 99.1 Letter to Shareholders, excerpted from the Nu Skin Enterprises, Inc. 2013 Annual Report to Shareholders</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">30 YEARS OF SUCCESS</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">A FOUNDATION FOR</div>

<div style="FONT-SIZE: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">SUSTAINED GROWTH</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Dear Shareholder,</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">As Nu Skin embarks on its thirtieth year, we continue to build on our solid foundation of success, which is anchored in our commitment to innovation, our sound business principles, and our mission to improve people's lives. As we look ahead, we are firmly focused on realizing our long-term goal of becoming the world's leading direct selling company.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In 2013, we made great strides towards this goal, with each geographic region contributing to impressive results that included:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">Record annual revenue of $3.177 billion</font>&#8212;a 49 percent improvement over 2012.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">Record earnings per share of $5.94</font>&#8212;a 69 percent increase over the prior year.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">Record profitability with a 17.4 percent operating margin</font>&#8212;up 145 basis points from 2012.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">$530 million in cash from operations</font>&#8212;up from $311 million in 2012.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">Strong 41 percent growth in actives<font style="FONT-WEIGHT: bold"> </font></font><font style="FONT-WEIGHT: bold">and 97 percent in sales leaders.</font></div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">A record $71 million in dividends </font>paid during the year.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In the Greater China region in 2013, we grew revenue by 148 percent to $1.36 billion as a result of strong revenue and sales force growth throughout the region, including significant growth in Mainland China. In the North Asia region in 2013, we grew revenue by 11 percent to $869 million. We also generated solid year-over-year growth rates in other regions including 15 percent in the South Asia/Pacific region; 30 percent in the Americas; and 7 percent in the EMEA region.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Yet our success has not been without its challenges.&#160;In January 2014, a series of negative media stories in Mainland China resulted in government investigations into our operations in that market.&#160;Because&#160;Mainland China's regulatory framework is unique, our business model in this market is different from our other global markets.&#160;Early in the process, we elected to take proactive steps to cooperate with regulatory authorities and demonstrate our commitment to operating in compliance with the laws of Mainland China. These actions included the suspension of business promotional meetings and the acceptance of applications for new direct sellers and sales employees. While these actions had, and will have, a negative impact on 2014 results, on May 1, 2014, we began accepting applications and holding corporate-led business meetings again in Mainland China, and we are moving forward to build a foundation for healthy, long-term growth.&#160;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">As we look ahead, we plan to continue our record of success by:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Capitalizing on the strength of our ageLOC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> anti-aging brand through continued product innovation.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Supporting our sales network and consumer group through channel innovation.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Leveraging our experienced management and global team of sales leaders to help drive revenue in every geographic region.</div>
</td>
</tr>
</table>
</div>

<div>
<table class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 11.5pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Increasing shareholder value by utilizing our balance sheet and cash flow.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">PRODUCT INNOVATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Nu Skin has established a legacy of product innovation by delivering highly differentiated products that provide exceptional benefits to a global consumer base that is anxious to live young. When it comes to anti-aging, Nu Skin is uniquely positioned to provide comprehensive anti-aging solutions that help battle the effects of aging on the inside and outside of the body. To this end, Nu Skin offers a balanced portfolio of nutrition and personal care products. This strength, in what we believe are the two most important battle grounds against aging, uniquely positions Nu Skin as a market leader in existing and emerging product categories.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In recent years, our product development efforts have been focused on advancing the understanding of the sources that influence the aging process, including the science of gene expression. This research has shaped our product development process, allowing us to introduce a comprehensive line of anti-aging products that we have branded as <font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-STYLE: italic">ageLOC</font>. Since launching the ageLOC brand in 2008, we have generated more than $3 billion in sales of ageLOC products, making it a key growth driver for our business.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In 2013, we added a significant new product system to our ageLOC anti-aging line-up, the ageLOC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> TR90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> weight management and body shaping system. Formulated with our exclusive anti-aging science, the proprietary TR90 system features four products and a comprehensive nutrition and lifestyle plan. While the initial introduction of the product system was extremely positive, our most recent research and usage results have indicated that there is a need for us to enhance the system by educating consumers on the benefits of maintaining lean muscle while reducing fat. Accordingly, we are making enhancements to the nutritional and lifestyle components of the system to help consumers better maximize their weight management and body shaping results. Overall, we believe that weight management and body composition represent a growing product category that has great potential.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In terms of anti-aging skin treatments, the at-home skin care device category is relatively new and expanding at a rapid pace. According to a 2012 Kline &amp; Company report, the market for at-home skin care devices has enjoyed significant growth globally. The report points to even greater opportunities for growth in the at-home skin care device market in the future. Nu Skin has been able to gain significant market share with its ageLOC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Galvanic Spa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> offering in Asia and we continue to see great opportunities to capture additional market share with future product introductions. We're also looking forward to introducing a new Nu Skin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Facial Spa unit to the U.S. market in the second half of the year.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">We remain optimistic about our product pipeline beyond 2014 and continue to make progress on two new product offerings scheduled for launch in 2015. Thanks to our product development team, we enjoy a robust pipeline, which we believe allows us to introduce new and innovative products over the next several years.</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">CHANNEL INNOVATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Another way that Nu Skin innovates is through our product launch process. We have developed a systematic approach for introducing new products that is designed to align our sales leaders around a process that maximizes their effectiveness and productivity and generates strong consumer demand for our products.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Since introducing our product launch process in 2009, we have made continual refinements as we have gained new insights through our application of the process on a global and regional scale. We have developed a systematic marketing cycle where we offer purchase windows, or limited-time offers (LTOs), before making products available on a full-time basis. In the early stages of the launch process, we provide our sales leaders with the training and messaging they can use to create product awareness and demand. Then, we typically execute global and regional LTOs, helping build even greater excitement within the sales network and helping generate significant levels of awareness and product trial among our consumer group. We typically make the new products available on a full-time basis about three to six months following these LTOs.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In 2013, we began a new product launch cycle with the limited-time global introduction of ageLOC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> TR90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> that generated approximately $550 million in sales, making it the largest product launch in our company's history. The TR90 LTO also helped drive solid results in each of our regions.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In 2014, we will continue to introduce the ageLOC TR90 system in the majority of our regions through regional LTO events. In addition, we are planning to introduce our highly successful ageLOC Tru Face<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Essence Ultra product in Greater China in the summer of 2014. This daily use anti-aging skin care serum has been very successful outside of the Greater China region. We anticipate introducing the product through a Greater China LTO in the summer of 2014 with the TR90 rollout coming later in the year. While this product launch process has added an impressive dynamic to our business, we continue to make refinements to maximize consumer demand and sales leader success.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">We continue to believe in the market potential for direct selling. For 30 years, Nu Skin has sold its products through this channel, a channel that utilizes person-to-person, word-of-mouth marketing to promote and sell products to consumers. According to the World Federation of Direct Selling Associations, the industry stood at nearly $167 billion in global revenue at the end of 2012, with nearly 90 million individuals involved in some form of direct selling.<font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">&#160;</font>Demographic trends continue to bode well for us. People are living longer globally, and the two most common concerns people face continue to be health and financial security.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">While direct selling is flourishing globally, growth rates are particularly robust in emerging markets. In some of these markets, to compete effectively we must adapt our product offering and business model to fit local economic, regulatory, and social dynamics.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">For example, we have an 11-year operating history in Mainland China and continue to see tremendous potential. During that time we've invested a tremendous amount of resources in the market, and our product offering has enjoyed great success. For instance, our ageLOC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Galvanic Spa<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has gained significant market share within the home-use skin care treatment device category in the market. We continue to believe that the appetite for high quality anti-aging products is both large and robust.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">As Mainland China's regulatory framework is unique, our business model in the market is different than our global business model. We are committed to working cooperatively with the Chinese government to support full compliance with the regulation of direct selling. We are also committed to investing in this important market as demonstrated by the recent completion of our new Innovation Park and regional headquarters in Shanghai, as well as manufacturing facilities and other initiatives unique to Mainland China.</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">A STRONG GLOBAL SALES FORCE AND MANAGEMENT TEAM</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Throughout our history, we have infused innovation into everything we do. This effort has produced an environment that has attracted many of the best and the finest people in the business.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">We have a strong and seasoned group of sales leaders who understand what it takes to be successful and are committed to our mission of improving people's lives. These people represent the finest leaders in the direct selling industry. They have been a driving force behind our 30 years of success and will continue to play that role in the future. Our sales leaders look to us to help them improve their lives and the lives of their sales teams and customers. We take our responsibility to our sales leaders seriously, and we work hand-in-hand with them to produce the kind of results that have made Nu Skin such a compelling success story for the past three decades.</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">INCREASING SHAREHOLDER VALUE BY INVESTING IN OUR FUTURE AND UTILIZING OUR BALANCE SHEET AND CASH FLOW</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">We are focused on rewarding our shareholders and have increased our dividend for the thirteenth straight year and purchased more than $141 million of our stock during the year.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In 2013, we made significant investments in advancing Nu Skin's long-term growth prospects with the completion of the Nu Skin Innovation Center and campus expansion at our corporate headquarters. And this year, we recently opened a new Innovation Park in Shanghai that will serve as our regional headquarters for Greater China. These new facilities both include new product development labs that we believe will help us maintain the momentum of our product ideation and development, as well as the appeal of our earnings opportunity going forward. Together, they represent confidence in our future and commitment to investing our resources to support our long-term growth potential.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">In our 30 years of operations, we have demonstrated a solid track record of success by exceeding aggressive business targets, providing highly innovative and differentiated products, attracting talented and dedicated sales people, and remaining focused on fiscal discipline and our mission to improve people's lives.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">We deeply feel our responsibility to all those who put their trust in us. This is the company that has stood the test the time for 30 years,<font style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-WEIGHT: bold">&#160;</font>and we are optimistic that we will continue to move the company forward to an even brighter future.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: ''Times New Roman'', Times, serif; TEXT-ALIGN: left">Sincerely,</div>

<div><br>
</div>

<div><img src="stevelundsignature.jpg"></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>STEVEN J. LUND</div>

<div>CHAIRMAN</div>

<div>NU SKIN ENTERPRISES</div>

<div>&#160;</div>

<div>&#160;</div>

<div><img src="trumanhuntsignautre.jpg"><br>
 TRUMAN HUNT</div>

<div>PRESIDENT, CEO</div>

<div>NU SKIN ENTERPRISES</div>

<div>&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>stevelundsignature.jpg
<TEXT>
begin 644 stevelundsignature.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!8`04#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`**:[K&A=V"J!DDG``JO8:E8ZI;FXT^\M[N#<5\RWE61<CJ,@XS0!:
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBD9@BEF(`'))[4`+
M12`AAD<@]#ZTM`!1110`5XSJWC[Q_P"$=9N)-=T2"?2!-GS8(FV+$6P-L@.`
M>G#C/L,U[-7#?$[.HZ+I_AJ+F;6[^&V(7EDB5A))(!WVA1GV-`&AI_Q(\':G
MN^S^(+)2O47#F`_^1`,UT=O=V]Y"LUK/%/$>CQ.&4_B*K7^AZ5JJ[=0TRSNQ
MZ3P*^/S%<U=?"SPK-*9[.TGTRY_AGT^X>%E/L,[1^5`':45Y9XBM?$_@#3)-
M6LO&9O+.)A_H>LH)&F;^ZL@^8L>P&.GM7I.FSSW6FVMQ<VYMKB6%'E@8Y,3$
M`E2>^"<?A0!:HHK&\0^*M'\+6/VK5KQ(`0?+CSEY2.RKU/;V&><4`;-<9XH^
M)&D>'Y);.V635-3C5F>UM3GR@/O&1NB`8R<\@<D8YK(5?%_Q`Y<S^&?#K<;1
MQ>W*_P#M,'_.X&H/&GAO1O#?AG1-%T^VCM-/U#6;6UOB#AYHB68[W//4`YSQ
MCCCB@##T;2_%7Q8N%U'Q%<R:?X;5MT=I;DH+C'8#J1ZNV>X7_9]@TG2+#0]/
MCL--M8[:UC&%CC''U)ZD^I/)JU%$D,2Q1HJ1HH5548"@=`!V%/H`****`"BB
MB@`IK.$4LQ`4#)).,"G57OK*#4;"XLKI/,M[B)HI4R1N5A@C(Y'!-`&-<>//
M"=K)Y<OB+30XZA;E6Q^1JI)\3?!D9PWB&T/^[N;^0KF;[X#^&9G\RRN]0LW!
MRH#K(@_!AG]:B_X5OXJT@+_9&O:1>(IR(M0TN-1_WV%9OY4`=6OQ-\%L<?\`
M"0V@^NX?TJS#X^\(SD!/$FE@GL]RJ_S(KBG3Q?IZ'^TOAUX>U:)>K6&Q,^^U
MP2?RJI)XH\!Q$)XB^'\FD2=&:XTA-@^C`!C^5`'JEMK>E7I`M-3L[@G_`)Y3
MJ_\`(U>S7DL5I\%];7*MI<6[L\TEJ?R)6M&U^&7A6X/F^'M>U.R_NMINI9`_
M'YC^M`'I5%>>GPEXXTH;M'\<-=*#Q;ZI;!PWUDY;\A3#X\U_PV57QGX<>*VX
M!U+3"98![LN25'U.?:@#T6O)-7^(^LZA\2[7PMX<B400W:PW<YCWLX4_O>O"
MJH##/4D<=L]%=?$6#4I!8^#[.37+]U!\Q5*6UN#T,LAQC_=')QC@UYKI5_H.
MD6?C!?$>K36'B2?4I(IKC3E/FO&&#$1<?*K,'R3@8VY[4`>U^)?$^E^%-);4
M=4FV1_=CC49>5NRJ.Y_0=3@5X)XP\4ZIXMOK:QU'6(=,MKF0'^SXY`8K:'KO
MN'R-SXP=G)]E.`8]!^&6I>*YWU:YFETW0"3(ES?2!YGBZ@]ATY+'`[C/2MG1
MO%W@K0TNEL?"4,MG;1M]DU&^VF6[92-QRRYR2RX50<9R0HSM!GH-A\2/`^F:
M=:Z;8ZM)<I:PI!&D-M-*Q55`&2%]!4LWQ0TZ*-Y4T'Q)-"@+&1-,8*!ZY8BL
M2/XK(-*TV/2]'.IZHZ)/?VFEJ9$M8B>3E1]_D#;V)Y(QS5O_`(M:Q:ZOI_G^
M%K_3=+D<F1[BW9IIE`Z(ORA3G'4G\J!'H?ACQ+;^*M+>_MK*^M(EE,06\B$;
M-@`[@`3D<XSZ@ULDXKSD_%@QS!I?!GB9+-ERDQL_F;G^[G&/?=7,>-/BEJ6L
MZ$\'A?3+Z"UGD6UDOIDVR&1L_NHE!/SX!Y!R.P'!H`[KPQXHU'Q-XNUDVR0C
MP[8'[+%)C+3S@C<P8'&T#/'HRGN<9KZWI-Q\4;Z^U/4K.VL]!M1:P?:9D4&X
ME^:1T)/4*`A'O69J7@.[TKPE:6\^NW-CH.F::TU];63;9;BX&YW^<]5.<`'.
M,#CTXZ_^'MO8?#OP]J`T>^O;V]N(YM0FL@TDJ0,"P54/`."!G'WAR<&@#U"[
M^+OA&"7R;6[N-1N#P(;*W=V/TR`#^=5_^$L\;:XNW0?![6,;=+O69?+V_6(?
M-^6:R8D\6:]IB:=X3T4>$-+A`9;BZ'ES3%?NKM`)`)Y).<^O4&[_`&#\3M7Q
M;:EXET[2[=!DSZ=$S2RGMG(7`^A'T-`&OH?@:9=4CUSQ/J;:SJ\9S"2NV"V_
MZYITS_M8]\9YKK[BY@L[>2XN98X8(U+/)(P55`ZDD\"O%_$DOBK1'32;CQ_=
M:A?3#$.GZ;IZ"YDXX+,IR@]\D^@.*6P^%_B_Q3H\8\6>*+J%`P>.S9C.1[O\
MP&?S_"@#JY?&FK>*KEK#P199M\E9=<NXRMO'C@^6I&9&_3/48YJ_X?\`AY8:
M7?'5]5N9=:UQSEKV[YV'_IFO1`.W4CL0.*JVOPUFB@2&7QIXE\M%"K';70@0
M#T"A3BGM\+]/<YDU_P`2R-_>?4V)_E0!W-8/C'P[;>*?#5SI=S+Y&[#Q3XYB
MD4Y5OZ'ID$C(ZU@/\)M'D/[S5]?<?W6U`D']*<OP?\'$@W%G=76/^>UY*<_D
MPH`G^&WB6_U_2+RVU7RWU#2[EK2>>+F.<CHX/3ZX],\9P.TJAI&BZ=H-B++2
M[.&TM@Q;RXA@$GN?4\#D^E7Z`"BBB@`HHHH`****`"BBB@`I&4,I5@"I&"".
M#2T4`8&I>$O"UU')+?Z'IC`*6>5K9`0`.3N`R/SKSC4/#_P<>U2^6_AL]W*_
M9KN3S?J(SEOI\O(YKV4J&!#`$$8(-9]GH.CZ?+YMEI-C;2_WX+=$//N!0!XN
MGAS7M0EC7P1>^+;>U)YN]5O/(@V_WD0`,P/KMK;U+X5^+M7T^.&_\=RW.`"U
MO)$QBSUY^;YOQ%>O8K+\0:[:>&](DU*^$GV>-D5BBYV[F"Y/H!GDT`>-W'@?
MQQX#BU#Q'I6K:>?*CWW%O;1;%=`.3Y>T)\H^;MT..O.]X7^'MWKAU#Q+XBU&
MUNY]<TWRXS#;@>4LD:@2#(&UPH`X'<^M6?$GCE?&-A<>&O!5O+J-Q>H8+B\,
M3)!;1,"'+%AR<9`^N1DX!]&TO3X])TFRTZ%F:*T@2!"W4A%"C/X"@#@+/X5W
MEU;6]EXE\4WNHZ;:HD4-A;K]GBV(`%#8/S<#V/O6;XB^%6B^'='?6=&TYKVX
MLG\^:UNG\Q9[<`^9&`>`<$D-@L"..<5ZY1CF@#`\'0^'AX?M[SPW9V]O972"
M0>4@#$],.1G+`Y!R3@@UOUY=?:1KWP[UBYU;PQ9G4?#]T_FW>E1\-"QZO$!V
M]@.G!&`"-BQ^+O@N\M?-?5#:N%R\-Q"X=/;@$$_0F@#N:\U5O^$V^*RE"'T?
MPP#R5^62\8_^RX_`IZ-575/'U_XTWZ)X!MKB3SALN-7D5HH[=3UVY&0<9YX/
M]T$\CN?"GAFR\(^'[?2;+YEC^:20C!ED/WF/U].P`':@##^);_;=,TOPZO)U
MK48;:4*?G6!3OD=?H%&?8UVP4*````.`!VKAKT_VE\9]+MGP8])TF6\0K_ST
ME<1$-_P$9%=U0!#=7=M8V[7%W/%!"GWI)7"J.<<D\=:X&_\`%.K>+M1GT3P4
MR1VT3>7>ZVXRD7JL0Z,WO_($-6QX_P#"M]XQT>VTNVU);*V-RKW7RDF1!V'T
M.#@C!('(Q6SH.@Z=X;TF+3=,@6*WC'_`G;NS'N3Z_P!*`,_PQX)TGPJ));1)
M)[^<?Z1?7#EY9CG)R3TYQT]!G)YKHZ**`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"D90RE6`(/!!'6EHH`9'%'#&(XHT1!T51@#\*?1
M10`4444`%9MYX?T;49_/O=)L+F;&/,GMD=OS(K2HH`9##%;PI##&D<2#"HB@
M!1[`4XL%&32T4`>;_#C44\3^*/%7BB")UM+IK:WM_,^\NR/YUXXZE37I%9VB
MZ%IGAZS>TTJSCM;=Y6E9$S@L>IY^@'L`!6C0`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
D4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>trumanhuntsignautre.jpg
<TEXT>
begin 644 trumanhuntsignautre.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!@`0H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBJFJ:A#I6E76H7)Q#;1-,_T49X]Z`(KS7-,T^]MK*\O[:"YN?]3%)*
M%9_H#6A7RKJ<&M>-;'7O'=[/Y45G)''&H'3+A0B'L%#`DXR<^I)KZ2\*ZG)K
M/A32M2FQYMS:QR28/&XJ,_KF@#8HHHH`****`"BBB@`HHHH`*,T5XQX3U&\U
M[X\:[<0WEPMC:K(K1!SLDV;8@".G7+#Z4`>ST444`%%%%`!112$XH`6BN=U7
MQYX7T5VCOM;M(Y%.&C5][CZJN37&W_QX\-P86RL[^\8GLBQC]3GT[=Z`/5**
M\4/QPU>_3=I'A"24;B`WG-+GIV5!CJ.]7-(^('Q%N-4M8M1\'[+.1PLK):3H
MP!XSDEL<^QZ?C0!Z_10.@HH`****`"BBB@`HHHH`****`"LS7]$M/$>B7.DW
M_F?9;E0'\MMK#!!!!]00#Z>QK3KS#XI>-=1T^XM/"WAT.=7U``-)%]^-&)4!
M3V8G//\`"!GC((`,+Q[J7A?PE\.KGP+IUW)/>':-A(=D/F"0F1@``>.G7IQB
MI_`GQ)DTW^Q/#6LZ#-IT,L4=O9W!W?O#]T$AAR&;'()QGTYJEK'PPT[PQ\/F
M@98[KQ%J=Q;VD=R_W4D>5?E3(X&`<GJ<GL<4[XHQF?QYX,T"W7<81'M;&3AI
M%7GCL(\T`>U7-U!96[W%U-'#"@R\DC!54>Y-.BFCFC62)U=&&593D$>H-?.O
MQ=\??\)%J/\`86FRAM,M),NZC_7RCC\5&>/4\\_+AGQ`U^?0-)T?P1IMY*AT
MR!&OY(I6^><C.P'T4DG'3D<?+0!]'LP7&3U.!3J^1?%7C/4O%#:<)I9E@L+>
M.*+<Q+-(%`>0GNQ(SGTQ[D^W?"?X@:KXS_M*WU2*V#V:Q%)(%9=V[<#N!)Y^
M4=,=30!WFM:U8>']*GU+4IQ#:PC+,>2?0`=R?2L7P7X\T_QNMZUA:W<*VKA2
MTZ`!@<XP02,\=.W%?/?Q&\:7?B_Q%-F3&G6LC1VD0X&T'&\C^\>OL,#ZKX0\
M<W?@_P`/:Y;V+D7UZ\"V^X;EBP)-[@=-WW!^7I0!]6T5XE\/?B7-HT.K:9XV
MOIUGLV#1M<DO+GHT>.I(.#WZGH`*W+3X[^%I[MH9K?4+:,9Q*\2L#]0K$_I0
M!Z-JMZNF:3>7[C<MM`\Q'J%4G^E>3_`&PSI6LZNZ@R3W(@W9.?E7<?U<?E6S
MXC\<Z=XF\#^(TT2.[N+>.QD62\:$I""1C:"V"20>PXS6/X#\0VGA#X)?VM-L
M+^=-Y49.#-*6(5?T&?0`T`1^,_&FNWOQ1TSPSX:NY(1;S(DY7!61SRVX=U5<
MY'KGN!7L?F*&"DC<1G&>U>&_!"U6]U77_%&H2(URO!E<@;2Y+R,1VZ#GT)JK
MH6I'QW\>TU.W;;:66YHF'4PQ@JI_X$S9_P"!&@#W^BO*/C+X[;1--70=-N#'
MJ-VNZ9T8AH8?8]BV"/89]0:\_LOC#KND>&],TVRD$]S!O-Q<7@,C/ER50$GH
M!CG/<`8Q0!Z;\5O&7B/PK:PC1K$""9#YFH.F\0MGA0.@/?+9!]*Y&Q^&OBWQ
MS90:AKOBT-;7"^8J*YN%P>F%!"#\.E='XW^+4&@7NF6=I9P7L5U;K<7BN<[8
MG'RJON1R<CICUXI:]JMM\/\`4C=>#I;:YMM1@:XN-+5BT4&1\MT-OW$YP1D`
MC&.@P`>9_$/PQHGA#5H-(TR\N;J[CCWWCRLNU2WW5"@<'')R3]X5]`^"_".D
M:1X<TIQI-DM^+6(RW!@3S"Y4$Y;&>OO7D'C_`,+1V$OA?2TG%YJVK3O-?7F<
MF>61HU!'3Y,EMHQ_6OHM0%4````8`':@!<48HHH`****`"BBB@`HHHH`****
M`"BBB@`KQ'X?1?\`"1_&7Q%X@N/F^QM(L(8?,N3Y:>W"*P_&O;J\-M+B#X8_
M%K59]8A,.DZLKO;W2QL50,X?`"]@<J1C(^4\`\@'H'B=O[0\:>%-'51(L<\N
MHS@$$HL495"1Z%W`_"N`^+GA+Q)JGC6PU'1K.YN$DMEMQ)!P8F#-G<1]T88<
MGU//%=!\.KRY\8>,M<\9/&\=B8Q86*R#GRP0Q]?0$X.,L?2O4<#TH`^=?$?P
MGU3PSI&B7VD6\^HZC'(7O1"ADVM\K(%0=5&&&>Y/N`+V@_!F_P!=\,W=_K<\
MMKK=W.)H3/EF09);S!W+YSZC`]2*]\Q10%SP+Q-\'-6M=&T2QT5%O)5DD:]E
M+A?WC[`#AC]T!<<>F>]6-#\(^+O`7C\6>AVK7>EWC1++>21@J(0P9\G("L`&
M'/4'CFO=:3`]!0!XAX?^",]MXRDN=5EAET>WF,L"*VYI_FRJN,8`X&[UZ#KD
M=9'\)=-3XA/XG:Y+PF8W(LFC&/./.[=Z!OF`QUQZ<^B8HH`\ZUSX0Z3X@\:-
MK][=2F"4*9[-!@2,JA0=X.0"`,@#/H177CPQH/V)+(Z+IS6L?W8FM4*C\"*U
MJ*`,;7="BU+PG?:);)';I/;/#$$7"H2.,`8X!Q7B_A?X4^)=2U.UL?%(DAT3
M3"VR'S@1(6.\A-IZ$GENO&,Y`Q]`T8%`'A>L?"GQ787FHZ=X7O8ET'5I%,T3
M2!3&H)(5B1NVC)'RG)&,BDN?AWXC^'=]8:[X3!U6>.!H[N)X\Y8]<(""5Z<`
MY!7T.![KBB@#PWPQ\)]0UZQU76?%ID&JWT;BV6=CNC<C'F.!W'&%[#/'3&AI
M?P5%OX*U2PN[FW;6KPCR[A,F.)4;<JC(SAB/FX]/2O8J,4`>1^!?@Y!IR7%U
MXJCM[ZYE0PI;_?CC3@;LD9WX'!&-H]^G?Z'X.T'PY87%EI>FPPP7/$X.7,HY
MX8L22.3P3CD^IK=HH`\$TO1;B3XYV6B3EY[+P^A\ABS$I"`TD0))Y*F1%SZ*
M!VKWL=*:L:*[.$4,V-Q`Y./6G4`%%%%`!1110`4444`%%%%`!1110`4444`%
M5KW3[+4K?[/?6=O=09W>7/$KKGUP1BK-%`%:QL+33;1+6QMH;:W3.R*%`BKD
MY.`..I)_&K-%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
4%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
